Providence Therapeutics CEO Brad Sorenson says his company's made-in-Canada coronavirus vaccine, the first to begin clinical trials, as he has said previously, needs more support from the federal government.
Read more here:
Providence Therapeutics manufactures mRNA vaccines formulated in lipid nanoparticles
Providence Therapeutics is a biotechnology company that develops mRNA vaccines for human use.
They manufacture their vaccines in house in Toronto, ON under GMP manufacturing conditions.
The mission is to provide safe and effective medicines for people suffering from diseases with unmet medical needs. The lead program is a personalized mRNA-based vaccine against cancer. Using advanced technology, they identify a patient's tumor mutations and develop a therapeutic vaccine that will elicit an immune response against the tumor cells.
Providence Therapeutics also has announced that first subject has been dosed in COVID-19 vaccine trial. Dosing has begun of volunteers in human clinical trials of its COVID-19 vaccine. PTX-COVID19-B is a messenger RNA (mRNA) vaccine and is the first fully made-in Canada COVID vaccine to reach this stage of development. Subjects will be monitored for a total of 13 months from the beginning of the trial. However, there will be enough data accumulated by April 2021 to move into Phase 2 in May 2021, pending regulatory approval. The clinical study of PTX-COVID19-B will be carried out in Toronto, ON.
No comments:
Post a Comment